Program
dapagliflozin
Also written as “Dapagliflozin”, “Dapagliflozin 10 mg” and “Dapagliflozin 10mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Renal Insufficiency, Chronic · Heart Failure · Diabetes Mellitus · Diabetes Mellitus, Type 1, led by 14 companies.
Drug pageDapagliflozin: every studyMany companies study it; this page follows only the 131 they lead. All 485 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 10910 open or running | phase 4since Jun 2, 2014 | Sep 9, 2005 | Dec 10, 2026phase 2 · NCT07222917 |
| LG Chemits history only | 60 open or running | phase 3since Feb 2, 2020 | May 24, 2018 | none ahead |
| Boryung Pharmaceuticalits history only | 32 open or running | phase 1since May 26, 2022 | May 26, 2022 | none ahead |
| Dong-A STits history only | 20 open or running | phase 3since Apr 20, 2020 | Dec 5, 2018 | none ahead |
| Hansoh Pharmaceutical Groupits history only | 20 open or running | phase 1since Apr 30, 2021 | Apr 30, 2021 | none ahead |
| autotelicbioits history only | 10 open or running | phase 1since Apr 20, 2021 | Apr 20, 2021 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 3since Nov 12, 2020 | Nov 12, 2020 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | no phasesince Nov 7, 2023 | Nov 7, 2023 | none ahead |
| dong-wha-pharmaceutical-co-ltdits history only | 10 open or running | phase 1since May 4, 2022 | May 4, 2022 | none ahead |
| George Clinical Ptyits history only | 10 open or running | phase 4since Nov 3, 2020 | Nov 3, 2020 | none ahead |
| Hamad Medicalits history only | 10 open or running | phase 3since Jul 22, 2018 | Jul 22, 2018 | none ahead |
| Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chairits history only | 11 open or running | phase 3since Jun 16, 2025 | Jun 16, 2025 | none ahead |
| Novartisits history only | 10 open or running | phase 2since May 21, 2021 | May 21, 2021 | none ahead |
| thpharm-corpits history only | 10 open or running | phase 1since Sep 8, 2023 | Sep 8, 2023 | none ahead |
- Named in AstraZeneca’s own pipeline as
zibotentan/dapagliflozin
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Fortrea, Parexel, Ground Zero Pharmaceuticals, PT Equilab International, Bristol-Myers Squibb, Q2 Solutions, PRA Health Sciences, Covance and Antaros Medical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since May 23, 2012.
- Aug 24, 2022Phase 2 study in Liver CirrhosisNCT05516498 · 205 enrolled · United States, Australia, Austria and more
- Oct 4, 2023Phase 3 study in Kidney DiseasesNCT06087835 · 1,835 enrolled · United States, Argentina, Australia and more
- Feb 2, 2024Phase 2 study in Liver CirrhosisNCT06269484 · 73 enrolled · United States, Australia, Belgium and more
- Feb 13, 2024Phase 3 study in Renal Insufficiency, ChronicNCT06268873 · 2,554 enrolled · United States, Argentina, Australia and more
- Aug 20, 2024Phase 4 study in Renal Insufficiency, ChronicNCT06610526 · 731 enrolled · China
- Nov 5, 2024Phase 3 study in Heart FailureNCT06677060 · 11,300 planned · United States, Argentina, Australia and more
- Dec 16, 2024Phase 3 study in Renal Insufficiency, ChronicNCT06742723 · 5,000 planned · United States, Argentina, Australia and more
- Apr 17, 2025Phase 2 study in Kidney DiseasesNCT06942910 · 224 enrolled · Russia
- May 5, 2025Phase 1 study in Lecithin Cholesterol Acyltransferase DeficiencyNCT06979388 · 14 enrolled · United Kingdom
- Oct 17, 2025Phase 2 study in Renal Insufficiency, ChronicNCT07222917 · 222 enrolled · United States, Argentina, Bulgaria and more
- Feb 5, 2026Phase 1 study in Renal Insufficiency, ChronicNCT07404137 · 26 enrolled · United States
- May 29, 2026Phase 3 study in Renal Insufficiency, ChronicNCT07624305 · 2,800 planned · United States, Argentina, Austria and more
- Jun 18, 20262 phase 3 studies in Diabetes Mellitus, Type 2NCT07662109, NCT07662044
- Jul 13, 2026Phase 1 study in Renal InsufficiencyNCT07754331 · 10 enrolled · United States
Ahead
- Dec 10, 2026Primary completion: phase 2 study in Renal Insufficiency, ChronicNCT07222917
- Feb 18, 2027Primary completion: phase 3 study in Kidney DiseasesNCT06087835
- May 31, 2027Primary completion: phase 4 study in Renal Insufficiency, ChronicNCT06610526
- Feb 24, 2028Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT06268873
TargetBeta
“The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Upon administration, dapagliflozin selectively targets and inhibits SGLT2, thereby preventing the reabsorption of glucose by the kidneys.”NCIt, read by Claude
“The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity”NCIt, by rule
“Sodium/glucose cotransporter 2 inhibitor; Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule
Other programs on SLC5A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| empagliflozinrule | Boehringer Ingelheim | phase 4 | 142 |
| ertugliflozinrule | Merck | phase 4 | 22 |
| Enavogliflozinrule | Daewoong Pharmaceutical | phase 3 | 25 |
| vicadrostat | Boehringer Ingelheim | phase 3 | 16 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
Studies
The newest 60 of 109 AstraZeneca leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07754331Renal Insufficiency · United States | 1 | Completed | Oct 6, 2026 | 10 |
| NCT07662109Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Recruiting | Jul 5, 2028 | 2,000 |
| NCT07662044Diabetes Mellitus, Type 2 · United States, Argentina, China and more | 3 | Recruiting | Jul 14, 2028 | 800 |
| NCT07624305Renal Insufficiency, Chronic · United States, Argentina, Austria and more | 3 | Recruiting | Jul 1, 2030 | 2,800 |
| NCT07404137Renal Insufficiency, Chronic · United States | 1 | Completed | Apr 2, 2026 | 26 |
| NCT07222917Renal Insufficiency, Chronic · United States, Argentina, Bulgaria and more | 2 | Active, not recruiting | Dec 10, 2026 | 222 |
| NCT06979388Lecithin Cholesterol Acyltransferase Deficiency · United Kingdom | 1 | Completed | Jul 12, 2025 | 14 |
| NCT06942910Kidney Diseases · Russia | 2 | Active, not recruiting | Sep 26, 2026 | 224 |
| NCT06742723Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Recruiting | Dec 18, 2029 | 5,000 |
| NCT06677060Heart Failure · United States, Argentina, Australia and more | 3 | Recruiting | Dec 17, 2029 | 11,300 |
| NCT06610526Renal Insufficiency, Chronic · China | 4 | Active, not recruiting | May 31, 2027 | 731 |
| NCT06268873Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 24, 2028 | 2,554 |
| NCT06269484Liver Cirrhosis · United States, Australia, Belgium and more | 2 | Completed | Dec 11, 2024 | 73 |
| NCT06087835Kidney Diseases · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 18, 2027 | 1,835 |
| NCT05516498Liver Cirrhosis · United States, Australia, Austria and more | 2 | Terminated | May 22, 2025 | 205 |
| NCT05266404Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus) · Germany | 1 | Completed | May 31, 2022 | 46 |
| NCT04991571Renal Insufficiency, Chronic · United States | 1 | Completed | Oct 22, 2021 | 27 |
| NCT04856007Healthy Volunteer · China | 1 | Completed | Jun 14, 2021 | 80 |
| NCT04595370Heart Failure · United States, Belgium, Bulgaria and more | 2 | Completed | Sep 22, 2023 | 153 |
| NCT04564742Heart Failure · Sweden, United Kingdom | 3 | Completed | Jul 5, 2023 | 4,017 |
| NCT04445714Diabetes Mellitus, Type 2 · India | 4 | Completed | Mar 14, 2023 | 196 |
| NCT03877237Heart Failure With Reduced Ejection Fraction (HFrEF) · United States, Brazil, Canada and more | 3 | Completed | Mar 7, 2020 | 313 |
| NCT03877224Heart Failure With Preserved Ejection Fraction (HFpEF) · United States, Argentina, Brazil and more | 3 | Completed | Jul 9, 2020 | 504 |
| NCT03619213Heart Failure With Preserved Ejection Fraction · United States, Argentina, Belgium and more | 3 | Completed | Mar 27, 2022 | 6,263 |
| NCT03608358Diabetes Mellitus, Type 2 · Thailand, Vietnam | 3 | Terminated | Aug 4, 2020 | 41 |
| NCT03387683Diabetes Mellitus, Type 2 · Finland, Sweden | 4 | Completed | Mar 19, 2019 | 53 |
| NCT03344341Diabetes Mellitus, Type 2 · China | 4 | Terminated | May 24, 2019 | 304 |
| NCT03338855Diabetes Mellitus, Type 2 · Netherlands | 4 | Completed | Nov 4, 2019 | 26 |
| NCT03199053Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Feb 1, 2023 | 256 |
| NCT03169959Diabetes Mellitus, Type 2 · United States | 1 | Completed | Aug 3, 2017 | 85 |
| NCT03138356Diabetes Mellitus, Type 2 · United Kingdom | 1 | Completed | Nov 28, 2017 | 126 |
| NCT03152084Diabetes Mellitus, Type 2 · Netherlands, Sweden | 4 | Terminated | Mar 20, 2020 | 24 |
| NCT03216278Lecithin Cholesterol Acyltransferase Deficiency · Brazil | 1 | Completed | May 22, 2018 | 284 |
| NCT03036150Renal Insufficiency, Chronic · United States, Argentina, Brazil and more | 3 | Completed | Jun 12, 2020 | 4,304 |
| NCT03036124Heart Failure · United States, Argentina, Brazil and more | 3 | Completed | Jul 17, 2019 | 4,744 |
| NCT02725593Diabetes Mellitus, Type 2 · United States, Hungary, Israel and more | 3 | Completed | Apr 6, 2020 | 72 |
| NCT02719132Diabetes Mellitus, Type 2 | 4 | Withdrawn | Nov 2017 | 0 |
| NCT02722239Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | May 5, 2016 | 40 |
| NCT02681094Diabetes Mellitus, Type 2 · United States, Canada, Czechia and more | 3 | Completed | Jul 15, 2017 | 905 |
| NCT02637037Diabetes Mellitus, Type 2 · United States | 1 | Completed | Apr 7, 2016 | 80 |
| NCT02582840Diabetes Mellitus, Type 1 · Japan | 1 | Completed | Jun 2016 | 42 |
| NCT02582814Diabetes Mellitus, Type 1 · Japan | 3 | Completed | Jun 15, 2017 | 151 |
| NCT02564926Diabetes Mellitus, Type 2 · Korea, Republic of | 4 | Completed | Jan 15, 2018 | 125 |
| NCT02547935Diabetes Mellitus, Type 2 · United States, Australia, Canada and more | 3 | Completed | May 18, 2018 | 459 |
| NCT02471404Diabetes Mellitus, Type 2 · Czechia, Germany, Hungary and more | 4 | Completed | Mar 13, 2017 | 939 |
| NCT02460978Diabetes Mellitus, Type 1 · United States, Argentina, Belgium and more | 3 | Completed | Sep 2, 2017 | 815 |
| NCT02426541Diabetes Mellitus, Type 2 · Finland | 4 | Completed | Apr 28, 2016 | 55 |
| NCT02419612Diabetes Mellitus · United States, Czechia, Germany and more | 3 | Completed | Aug 29, 2017 | 444 |
| NCT02413398Diabetes Mellitus, Type 2 · United States, Bulgaria, Canada and more | 3 | Completed | Nov 7, 2017 | 321 |
| NCT02284893Diabetes Mellitus, Type 2 · United States, Hungary, Mexico and more | 3 | Completed | Sep 20, 2016 | 461 |
| NCT02279407Non-alcoholic Fatty Liver Disease · Sweden | 2 | Completed | Dec 2015 | 223 |
| NCT02268214Diabetes Mellitus, Type 1 · United States, Australia, Austria and more | 3 | Completed | Jan 4, 2017 | 833 |
| NCT02223065Diabetes Mellitus, Type 2 | 1 | Completed | Dec 2014 | 36 |
| NCT02157298Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Feb 2015 | 266 |
| NCT02096705Diabetes Mellitus · China, Korea, Republic of, Singapore | 3 | Completed | Jan 28, 2016 | 477 |
| NCT02060201Diabetes Mellitus, Type 2 | 1 | Completed | May 2014 | 72 |
| NCT01730534Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Sep 11, 2018 | 17,190 |
| NCT01662999Diabetes Mellitus, Type 2 · United States | 1 | Completed | Nov 2012 | 42 |
| NCT01646320Diabetes Mellitus, Type 2 · United States, Czech Republic, Mexico and more | 3 | Completed | Aug 2014 | 320 |
| NCT01606007Diabetes Mellitus, Type 2 · United States, Canada, Korea, Republic of and more | 3 | Completed | Jan 2014 | 1,282 |
How it is read
Names in the registry
- “Dapagliflozin”, 90 entries
- “dapagliflozin”, 18 entries
- “Dapagliflozin 10 mg”, 6 entries
- “Dapagliflozin 10mg”, 5 entries
- “Dapagliflozin/metformin XR 10/1000mg”, 4 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 80 studies
- Renal Insufficiency, Chronic, 8 studies
- Heart Failure, 7 studies
- Diabetes Mellitus, 7 studies
- Diabetes Mellitus, Type 1, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.